
|Articles|February 1, 2005
Glaucoma agent lowers IOP by dual mechanism
New Orleans—Travoprost 0.004% (Travatan, Alcon Laboratories) lowers IOP by both increasing outflow facility and improving uveoscleral outflow, according to the results of a clinical study designed to investigate the mechanism of action of travoprost.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Evolving glaucoma therapy: A new era of interventional strategies
2
Throwback Series: The eye that found a cancer
3
Development of maculopathy associated with systemic medications
4
Proactive strategies and sustained delivery advance glaucoma care
5

















































.png)


